Ministerio da Saude (MINSA), 2001. Programa Nacional de Controle da Malária. Boletim Informativo. Luanda, Angola. Abril 2001.
Guthmann J-P, Ampuero J, Fortes F, van Overmeir C, Gaboulaud V, Tobback S, Dunand J, Saraiva N, Gillet P, Franco J, Denoncin A, van Herp M, Balkan S, Dujardin JC, D’Alessandro U, Legros D, 2005. Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola. Trans R Soc Trop Med Hyg 99 :485–492.
World Health Organization, 2005. Global AMD database. AFRO. Available at: http://www.who.int/malaria/amdp/amdp_afro.htm. Accessed October 11, 2005.
World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: World Health Organization.
World Health Organization, 1991. Basic Malaria Microscopy, Parts I and II. Geneva, Switzerland: World Health Organization.
Brockman A, Paul REL, Anderson TJC, Hackford I, Phaiphun L, Looareesuwan S, Nosten F, Day KP, 1999. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the north western border of Thailand. Am J Trop Med Hyg 60 :14–21.
Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, Guthmann J-P, Barnes K, Myint HY, Adjuik M, Olliaro P, Pukrittayakamee S, Looareesuwan S, Hien TT, Farrar J, Nosten F, Day NP, White NJ, 2004. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 48 :4271–4280.
Martensson A, Stromberg J, Sisowath C, Msellem MI, Pedro Gil J, Montgomery SM, Olliaro P, Ali AS, Bjorkman A, 2005. Efficacy of artesunate plus amodiaquine versus that of artemether + lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. J Infect Dis 41 :1079–1086.
Price R, Nosten F, 2001. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. Drug Resist Update 4 :187–196.
2005 The global fund to fight AIDS, tuberculosis, and malaria. Available at: http://www.theglobalfund.org/search/portfolio.aspx?countryID=AGO&lang=en. Accessed October 13, 2005.
Malenga G, Palmer A, Staedke S, Kazadi W, Mutabingwa T, Ansah E, Barnes KI, Whitty CJ, 2005. Antimalarial treatment with artemisinin combination therapy in Africa. BMJ 331 :706–707.
Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW, 2005. Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross-sectional study. BMJ 331 :734–738.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||279||115||4|
In April 2004, 137 children 6–59 months of age with uncomplicated Plasmodium falciparum (Pf) malaria (Caala, Central Angola) were randomized to receive either artemether-lumefantrine (Coartem) or artesunate + amodiaquine (ASAQ). After 28 days of follow-up, there were 2/61 (3.2%) recurrent parasitemias in the Coartem group and 4/64 (6.2%) in the ASAQ group (P = 0.72), all classified as re-infections after PCR genotyping (cure rate = 100% [95%CI: 94–100] in both groups). Only one patient (ASAQ group) had gametocytes on day 28 versus five (Coartem) and three (ASAQ) at baseline. Compared with baseline, anemia was significantly improved after 28 days of follow-up in both groups (Coartem: from 54.1% to 13.4%; ASAQ: from 53.1% to 15.9%). Our findings are in favor of a high efficacy of both combinations in Caala. Now that Coartem has been chosen as the new first-line anti-malarial, the challenge is to insure that this drug is available and adequately used.